This came across the wire yesterday. Late entry into conference today? New developments?
Biostage to Participate at the Alliance for Regenerative Medicine's 5th Annual Cell & Gene Therapy Investor Day
Wednesday 04/26/2017 07:35 AM ET - PR Newswire via Dow Jones News
HOLLISTON, Mass., April 26, 2017 /PRNewswire/ -- Biostage Inc., (Nasdaq: BSTG), ("Biostage" or the "Company), a biotechnology company developing bioengineered organ implants to treat cancers and other life-threatening conditions of the esophagus, bronchus and trachea, announced today that it will participate in the Alliance for Regenerative Medicine's ("ARM") 5(th) Annual Cell & Gene Therapy Investor Day being held on Thursday, April 27, 2017 in Boston, MA.
About ARM's Cell & Gene Therapy Investor Day
This one-day, high impact program provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe. For more information, please visit www.arminvestorday.com.
